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Benzo[a]pyrene (B[a]P), a well-known environmental pollutant, is bioactivated by cytochrome P450 (CYP) enzymes to 3 To whom correspondence should be addressed acquire its mutagenic and carcinogenic properties (1, 2) . The Email: schwarz@mdc-berlin.de first step of activation is the formation of B[a]P-7,8-epoxide, Cytochrome P450 1A1 (CYP1A1) plays a key role in the followed by hydrolysis by epoxide hydrolase (EH) to the metabolism of carcinogens, such as benzo [ 
a]pyrene (B[a]P)
B[a]P-trans-7,8-dihydrodiol (7,8-diol) , which is further metaband metabolites to ultimate carcinogens. Three human olized by CYP enzymes to the ultimate genotoxic (Ϯ)-B[a]Pallelic variants, namely wild-type (CYP1A1.1), CYP1A1. 2 r-7,t-8-dihydrodiol-t-9,10-epoxide (DE2) (3, 4) . Cytochrome (I462V) and CYP1A1.4 (T461N), were coexpressed by P450 1A1 (CYP1A1) and CYP1B1 have been shown to be coinfection of baculovirus-infected insect cells with human the principal catalysts of metabolism of B[a]P and other NADPH-P450 reductase. These recombinant enzymes (in polycyclic aromatic hydrocarbons. In numerous studies microsomal membranes) were used to analyze whether (5-12), CYP1A1 was the enzyme that exhibited the greatest CYP1A1 polymorphisms affect catalytic activities towards capacity for B[a]P metabolism and particularly for production
B[a]P and B[a]P-7,8-dihydrodiol. The complete spectrum
of DE2. B[a]P was twice as cytotoxic in human than in rat of phase I metabolites, including the tetrahydrotetrols CYP1A1-expressing V79 cells (13) .
resulting from hydrolysis of the ultimate carcinogen, B[a]P-
The human CYP1A1 gene is polymorphic. Beside wild-type 7,8-dihydrodiol-9,10-epoxide, was examined by HPLC.
CYP1A1*1A (protein: CYP1A1.1) (14), so far seven CYP1A1 Wild-type enzyme showed the highest total metabolism of alleles have been identified (see URL: http://www.imm.ki.se/ B[a]P, CYP1A1.2 was~50%, and CYP1A1.4~70%. K m CYPalleles), two of which show nucleotide exchange associvalues for all metabolites with CYP1A1.2 were generally ated with an amino acid exchange near the active site of the significantly lower than with wild-type enzyme (e.g. B[a]Penzyme: CYP1A1*2B (protein: CYP1A1.2, I462V variant) (15) 7,8-diol formation: 13.8 µM for wild-type, 3.5 µM for and CYP1A1*4 (protein: CYP1A1.4, T461N variant) (16) . The CYP1A1.2 and 7.7 µM for CYP1A1.4). Addition of epoxide nucleotide exchange 2455AϾG, which results in the amino acid hydrolase markedly increases the relative diol-to-phenol substitution I462V, was found in Caucasians to be exclusively activities by all three variants. However, CYP1A1.4 exhibits linked with 3801TϾC in forming allele CYP1A1*2B (15) (16) (17) (18) . the greatest efficiency to produce diol species. Each variant The latter nucleotide mutation alone forms allele CYP1A1*2A. produced the diol epoxides from B[a]P-7,8-dihydrodiol.
Allele frequencies of CYP1A1*2A are 6.6-18.1% in a Cauca-CYP1A1.1 exhibited with 10.4 pmol/min/pmol CYP1A1 the sian population (16) (17) (18) and 33% in Japanese (19) ; respective greatest total rate for 7,8-diol metabolites followed by frequencies of *2B are 2.2-8.9% (16) (17) (18) and 19.8% (20) . CYP1A1.2 (7.2 pmol/min/pmol CYP1A1) and CYP1A1.4 CYP1A1*4 occurs with 2.0-5.7% of alleles in Caucasians (16-(5.5 pmol/min/pmol CYP1A1). All enzyme variants pro-18). An increased risk for lung cancer was found in carriers duced about three times more diol epoxide 2-derived of CYP1A1*2A and *2B alleles following epidemiological metabolites than diol epoxide 1-derived ones, whereby investigations (16, (19) (20) (21) (22) (23) (24) . A strong association between the both rare allelic variants exhibited statistically significantly CYP1A1*4 allele and the risk of endometrial cancer was increased formation of diol epoxide 2. This study showed reported (25), but not for lung cancer (16) . Another study that the three CYP1A1 variants had different enzyme discussed breast cancer susceptibility associated with individual kinetics properties to produce both the diol metabolites CYP1A1 genotypes (26) . However, ethnic, regional or statistical from B[a]P and the ultimate mutagenic species diol epoxide issues complicate elucidation of an association between specific hereditary CYP variations and cancer incidence (17, 18, 27 volume 990 µl) and preincubated for 3 min at 37°C. For certain assays, EH and anti-rat OR antibodies were purchased from Daiichi Pure Chemicals was included in the preincubation mixture because of its effect on the (Tokyo, Japan) and anti-goat secondary antibodies (horseradish peroxidasemetabolism of B[a]P (37). Typical EH addition was 250 µg per 20 pmol labeled) from Boehringer Mannheim (Germany). In western blot analysis we CYP1A1. The reaction was started by addition of 10 µl of NADPH and used, as negative and positive control for the expression of CYP1A1 and continued for 30 min at 37°C (final volume: 1 ml, final concentration: 10 µM OR, microsomes prepared from uninfected Sf9 cells, CYP1A1-supersomes B[a]P substrate, 0.5 mM NADPH). The reaction was stopped by addition of (Gentest, Woburn, MA) and microsomes prepared from Sf9 cells expressing 1 ml ice-cold acetone. All assays were performed in parallel with the three only OR, respectively. For supplementation of assays with EH, lymphoblastoidenzyme variants and with equal CYP concentration, to minimize variation. cell microsomes containing microsomal EH were purchased from Gentest.
Substrate stock solutions were prepared as follows. A certain amount of [7,10- redissolved with 50 µl of methanol, sonicated in an ultrasonication bath and Construction and preparation of recombinant baculoviruses injected into the HPLC apparatus. Wild-type cDNA for human CYP1A1 was kindly provided by Dr F.J.
Metabolism of 7,8-diol was assayed analogously with only minor modificaGonzalez (National Cancer Institute, NIH, Bethesda, MD). Construction of tions. Substrate stock solutions were prepared in methanol. The reaction was the CYP1A1.2 and CYP1A1.4 variants, cloning of cDNAs carrying the stopped on ice by adding 100 µl of 1 M potassium phosphate buffer (pH 3.5) and held on ice for 1 h. Following this, 10 µl methanol containing 10 µg respective mutation into baculovirus transfer vectors pBlueBac4.5 under 1,1'-bi-2-naphthol as internal standard was added, followed by extraction of control of the polyhedrin promoter, cotransfection of Sf9 insect cells and the substrate and products as described above for the B[a]P assay. preparation of large-scale high-titer stocks of recombinant baculovirus for the expression of the variants in insect cells were done as described (30) .
HPLC analysis Recombinant baculovirus for coexpression of OR was kindly provided by Dr B[a]P metabolism was analyzed using an HPLC system (Shimadzu) consisting F.J.Gonzalez.
of two solvent delivery systems LC-10 AD VP, a UV detector SPD-10 A VP and run with CLASS VP software. Separation was performed with a reversed-
Coexpression by coinfection of human CYP1A1 variants and OR in Sf9
phase column (Nucleosil 100-5 C18, 5 µm, 250ϫ4 mm; Macherey-Nagel, insect cells Dueren, Germany) at 25°C with a flow rate of 0.8 ml/min using a linear Sf9 cells (400 ml) seeded at 1.8ϫ10 6 cells/ml were simultaneously infected methanol-water gradient of 60% methanol rising to 100% in 80 min. 7,8-at a multiplicity of infection of 3.2 for baculovirus-CYP1A1 and 1.1 for Diol metabolism was analyzed analogously, at 40°C with a flow rate of 1 ml/ baculovirus-OR. Twenty to twenty-four hours post-infection, media were min. Initial solvent conditions were 40% methanol with a linear gradient to fortified with δ-amino levulinic acid (0.5 mM final). Cells were harvested 47.3% in 35 min followed by isocratic elution with 60% methanol for another after~73 h. The optimal time to harvest was based on CYP content and 35 min. Absorbance was monitored at 254 nm (B[a]P) and 344 nm (7,8-diol) , enzymatic activity assessed by CO difference spectra and 7-ethoxyresorufin respectively. 14 C radioactivity was evaluated using a radioactivity monitor O-deethylation (EROD) activity. The harvested cell pellet was washed twice (LB 507 A, Berthold, Wildbad, Germany). Metabolites were identified by with PBS and resuspended in phosphate buffer. Catalytical studies were comparison with retention times of authentic standards. The level of each performed with microsomes prepared according to Buters et al. (33) . Microtetrol was determined by comparison with a standard curve generated from somal pellets were resuspended in 100 mM standard phosphate buffer [pH the absorption areas of authentic tetroles analyzed in parallel under identical 7.4, 1 mM EDTA, 0.1 mM dithiothreitol, 20% glycerol (vol/vol)], aliquoted assay and extraction conditions using the internal standard. and stored at -80°C.
Results

Immunoblot and analytical methods
Microsomal proteins were electrophoresed in 10% SDS-PAGE and transferred
Characterization of CYP1A1 variants coexpressed with OR in
to a nitrocellulose filter. The filter was incubated overnight with an antibody Sf9 insect cells mixture of 1:1000 dilution of goat anti-rat CYP1A1/1A2 and 1:10 000 dilution
The three CYP1A1 variants could be successfully coexpressed of goat anti-rat OR. The blots were developed using 1:10 000 dilution of horseradish peroxidase-labeled anti-goat IgG as secondary antibody and with OR in Sf9 insect cells as native, spectrally and catalytically slightly higher, indicating only minor differences in kinetic behavior. 4,5-diol metabolite formation was almost negligible in the Immunoblot analysis proved expression of all CYP1A1 absence of EH. Total quinone production was 0.92, 0.42 and variants and OR, as revealed by simultaneous probing of the 0.72 pmol/min/pmol CYP for CYP1A1.1, CYP1A1.2 and blot with polyclonal goat anti-rat CYP1A1/1A2 and goat anti-CYP1A1.4, respectively. Thus, the summed rates of phase I rat OR antibodies (Figure 1, lanes 1-3) . The same antibodies metabolites were 2.79, 1.27 and 1.83 pmol/min/pmol CYP for did not detect any immunoreactive proteins in microsomes CYP1A1.1, CYP1A1.2 and CYP1A1.4, respectively. Taken from uninfected Sf9 cells as negative control (lane 5). As together, total metabolism of B[a]P by wild-type enzyme expected, they showed strong immunoreactivity with baculoalways exhibited the highest activity (3.3 pmol/min/pmol; virus-expressed wild-type CYP1A1 in CYP1A1-supersomes 100%), CYP1A1.2 was 1.55 (~50%), and CYP1A1. 4 
(lane 6, positive control) as well as with OR in microsomes (~70%). expressing OR exclusively (lane 4). EH was added because it might have a large effect particu-B[a]P metabolism by human CYP1A1 variants
larly on diol metabolites (37). Our results with insect cell microsomes show that diol and phenol metabolite production CYP1A1 variants were assayed using B[a]P as substrate with and without addition of EH. The B[a]P-trans-9,10-dihydrodiol was differently affected by EH. Whereas 9,10-diol and 4,5-diol formation was greatly increased, the influence on 3-OH (9,10-diol), B[a]P-trans-4,5-dihydrodiol (4,5-diol), 7,8-diol, 9-hydroxybenzo[a]pyrene (9-OH), 3-hydroxybenzo[a]pyrene (3-and 9-OH was only slight, and formation of 7,8-diol was almost unaffected. Thus, the overall effect of increased EH OH) and quinone metabolites were well separated. We could not detect the 7-hydroxybenzo[a]pyrene metabolite eluting activity resulted in an increased formation of diols at the expense of phase I metabolites for all CYP1A1 variants. shortly before 3-OH under our conditions. The quinones were identified by comparison with published chromatograms K m and V max values for major phenol and diol metabolites were determined (Table III) Table II. with that of wild-type enzyme, whereas that of CYP1A1.4 is comparable with that of wild-type enzyme. A similar relationIn the absence of EH, total phenol product formation was 1.87, 0.85 and 1.11 pmol/min/pmol CYP for CYP1A1.1, ship holds for 7,8-diol formation. On the other hand, the K m for 9,10-diol production by CYP1A1.2 is comparable with that CYP1A1.2 and CYP1A1.4, respectively. Diol metabolite formation was determined to be 0.51 (CYP1A1.1), 0.28 for CYP1A1.4, but both are less than half that of the wildtype. Figure 2 depicts the efficiency in the formation of (CYP1A1.2) and 0.50 pmol/min/pmol CYP (CYP1A1.4). The Material and methods. Each variant of CYP1A1 produced the products leading finally to mutagenic species, i.e. the combined diol epoxides 1 (syn) and 2 (anti) which finally hydrolyze efficiencies for (7,8-diol ϩ 9,10-diol) formation related to non-enzymatically to the four tetrol metabolites (Ϯ)-B[a]Pthose for (3-OH ϩ 9-OH) formation. CYP1A1.4 appears to r-7,t-8,c-9,c-10-tetrahydrotetrol (RTCC), (Ϯ)-B[a]P-r-7,t-8,chave the greatest capacity in terms of this ratio of diol-phenol 9,t-10-tetrahydrotetrol (RTCT), (Ϯ)-B[a]P-r-7,t-8,t-9,c-10-production. Relative efficiencies of diol formation by wildtetrahydrotetrol (RTTC) and (Ϯ)-B[a]P-r-7,t-8,t-9,t-10-tetrahytype enzyme and CYP1A1.2 are similar in the absence of EH; drotetrol (RTTT) (8) . Additional minor, unknown oxidation however, wild-type enzyme exhibited a significantly greater products were present, some of which may represent triols. efficiency in the presence of EH (P Ͻ 0.05; ANOVA). EH Assays of incubations with uninfected microsomes as negative supplementation led to a pronounced overall increase (2-3-control not expressing CYP1A1 showed no production of 7,8-fold) in relative diol-phenol activities of all CYP1A1 variants. diol metabolites, and neither did assays performed without 7,8-diol metabolism by human CYP1A1 variants NADPH (not shown).
The summed rates RTCCϩRTCT, representative for (Ϯ)-Separation of all 7,8-diol oxidation products could be well achieved according to the HPLC method described in the B[a]P-r-7,t-8-dihydrodiol-c-9,10-epoxide (DE1) formation, -diol at the given concentrations for 15 min at 37°C, as described in Materials and methods. After incubation at pH 3.5 to complete hydrolysis, 1,1'-bi-2-naphthol as standard for chromatography was added followed by substrate and product extraction as described. b Two groups of tetrol metabolites are discriminated: (i) DE2-derived, RTTC ϩ RTTT; (ii) DE1-derived, RTCC ϩ RTCT. Rates are expressed in pmol/min/pmol CYP1A1 as mean Ϯ SD, determined from at least three separate HPLC analyses. Average DE2:DE1 ratios, as calculated from the DE2:DE1 ratios with specified substrate concentrations; ANOVA yielded the means and standard deviations shown.
and RTTCϩRTTT, representative for DE2 formation, were increased risk of cancer (4, 38) . We concentrate our discussion measured at three different 7,8-diol concentrations (Table IV) .
on which allelic variant of human CYP1A1 is the most The rates only slightly increased with substrate concentration effective catalyst of B[a]P to diols and of 7,8-diol to diol indicating approximation of saturation conditions. CYP1A1.1 epoxide DE2, as discussed below. had the greatest total rate for 7,8-diol metabolism at all Most active in B[a]P metabolism was wild-type CYP1A1.1, substrate concentrations (averaged for the three concentrations followed by enzyme variants CYP1A1.4. and CYP1A1.2 investigated: 10.4 pmol/min/pmol CYP), followed by (Table II) . Here, differential substrate specificity becomes CYP1A1.2 (7.2 pmol/min/pmol CYP) and CYP1A1.4 (5.5 evident, since, conversely, EROD activity tended to be highest pmol/min/pmol CYP). The DE2-derived metabolites were in CYP1A1.4 and lowest in wild-type enzyme (Table I) . There formed at a clearly higher rate by each CYP1A1 compared is another observation concerning substrate specificity. Table III with DE1-derived metabolites. DE2:DE1 ratios in Table IV shows that K m values of B[a]P for production of all measured indicate a slightly higher value for both rare variants as metabolites were lowest with CYP1A1.2 (up to a quarter of compared with wild-type enzyme.
wild-type enzyme). This enzyme species is distinct due to an I462V amino-acid exchange just close to the region of substrate Discussion binding. Interestingly, the neighboring change of T461N, occurring in CYP1A1.4, is of lesser consequence on K m .
Controlled coexpression of CYP1A1 and OR
Such differential K m values were not observed with The baculovirus/insect cell expression system gives relatively 7-ethoxyresorufin (Table I) , but were also seen with steroid high levels of expression of native and functionally active hormones as substrates (30) . CYP1A1 (33) . Using this approach, we had previously
The total B[a]P metabolism rate determined in our study is expressed the three CYP1A1 variants and characterized their roughly comparable with data reported by Kim et al. (11) for catalytic properties in steroid hydroxylations employing a insect-cell expressed human wild-type CYP1A1. Prior data on reconstituted system with cumene hydroperoxide as the oxygen B[a]P metabolism by other variants of CYP1A1 are from donor (30) . In the present study, we took advantage of the Kawajiri et al. (20) who found 1.5-fold higher aryl hydrocarbon coexpression by coinfection approach to prepare CYP1A1 hydroxylase activity for CYP1A1.2 compared with wildvariants using two different recombinant baculoviruses for type enzyme. Likewise, Persson et al. (29) investigated the coexpression of CYP1A1 and OR. To compare activities of the formation of 3-OH-B[a]P, but observed no difference in CYP1A1 variants-our major objective-it was of particular activities of both variants. On the other hand, Zhang et al. importance that coinfection allowed a fine adjustment of the OR:CYP ratio and that we used simple microsomal prepara-(28) measured rates of CYP1A1.1-and CYP1A1.2-mediated tions. By changing the relative multiplicities of infection by diol formation for higher B[a]P concentrations. While the the two viruses we achieved molar OR:CYP ratios of around authors could not detect any metabolites at 10 µM B[a]P, their 20 in microsomes prepared for all variants, thus establishing data for diol formation at 40 and 100 µM are similar to our standardized conditions to elucidate possible differences in results for 10 µM B[a]P. As in our study, CYP1A1.2 was catalytic properties of the variants. Microsomes prepared from clearly the enzyme variant exhibiting a significantly smaller this system exhibited enzyme-kinetic properties in standard activity (about half) compared with wild-type. Why our data assays (EROD) comparable with those with purified and and those of Zhang et al. disagree with those of Kawajiri reconstituted CYP1A1, as expressed in the baculovirus (33) et al., who used a yeast-expression system with relative low and Escherichia coli system (28), and also comparable with level of CYP expression, is not obvious. yeast-expressed microsomal CYP1A1 (29).
There are interesting differences between the CYP1A1 Differential formation of precarcinogenic B[a]P metabolites variants (Table II) . Total diol formation by CYP1A1.1 and by CYP1A1 variants CYP1A1.4 was approximately equal, whereas that by CYP1A1.2 was only half. However, the markedly lower rates B[a]P metabolism leads to the formation of phenols, quinones of phenol formation by CYP1A1.4 compared with CYP1A1.1 and epoxide-derived diol products. Phenols and quinones have are contrasted by preferred formation of premutagenic diol been found to be non-or less mutagenic compared with diols products by the CYP1A1.4 variant. These differences become (1-3) . In contrast, diol epoxides, particularly DE2 (the major ultimate carcinogenic species), have been associated with an evident by comparing the diol-phenol formation efficiency of CYP1A1 variants (Figure 2 ). CYP1A1.4 is the variant exhibit-(Ah receptor polymorphism) than polymorphism in the CYP1A1 gene (42). Further, the impact of CYP1A1 on cancer ing the highest relative diol product-formation potency.
It has been known for a long time that EH greatly affects risk may be modified by possible coregulation with detoxifying enzymes such as glutathione S-transferase M1 (43, 44) , or the pattern of B[a]P metabolites (37, 8) . From our studies it is evident that the formation of 9,10-diol is greatly increased, as by interference from other polymorphic enzymes, such as myeloperoxidase (45) or microsomal epoxidehydrolase (46), shown in Tables II and III for all three enzyme variants. Formation of phenols is little affected by EH. Therefore all that also metabolize B[a]P or its metabolites. CYP1A1 variants showed a marked increase in the diol-phenol formation efficiency (Figure 2) . Thus, EH activity shifts B[a]P
